Related Experiment Videos

Induction of specific-locus and dominant lethal mutations in male mice by trophosphamide

U H Ehling1, A Neuhäuser-Klaus

  • 1GSF-Forschungszentrum für Umwelt und Gesundheit, GmbH, Institut für Säugetiergenetik, Neuherberg, Oberschleissheim, Germany.

Mutation Research
|May 1, 1994
PubMed

Insights

Trophosphamide causes genetic mutations in mouse sperm, with peak effects observed 1-4 and 9-16 days after treatment. These mutations are likely intergenic, impacting DNA at specific gene locations.

Area of Science:

  • Genetics
  • Toxicology
  • Reproductive Biology

Background:

  • Trophosphamide is a chemotherapeutic agent.
  • Understanding its genotoxic effects is crucial for risk assessment.
  • Spermatozoa and spermatids are key targets for mutagenicity studies.

Purpose of the Study:

  • To investigate the mutagenic potential of Trophosphamide.
  • To determine the mutation induction pattern in mouse germ cells.
  • To characterize the nature of Trophosphamide-induced mutations.

Main Methods:

  • Mice were treated with Trophosphamide.
  • Dominant lethal mutations were assessed through mating trials.
  • Specific-locus mutations were analyzed post-treatment.
  • Mutation induction patterns were mapped across different mating intervals.

Main Results:

  • Trophosphamide induced both dominant lethal and specific-locus mutations.
  • Two distinct peaks in mutation induction were observed at 1-4 and 9-16 days post-treatment.
  • The data suggests that induced mutations are primarily intergenic.

Conclusions:

  • Trophosphamide exhibits significant genotoxicity in mouse germ cells.
  • The temporal pattern of mutation induction provides insights into spermatogenesis.
  • Intergenic mutations are the likely outcome of Trophosphamide exposure.

Related Concept Videos